Clinical trial NCT04090736: Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Official title: A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Leukemia, Myeloid, Acute
Keywords: Leukemia
Myeloid
Acute
Pevonedistat
Azacitidine
Randomized
Clinical trial
Lead sponsor: PETHEMA Foundation
Sponsor class: OTHER
Collaborators: name: Millennium Pharmaceuticals, Inc.
name: Dynamic Science S.L.
First posted: 2019-09-16
Enrollment: 302
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, prospective, multicenter, open label study.
Primary purpose: TREATMENT

Brief summary: Randomized phase III, multicentre, open label clinical trial to compare pevonedistat in combination with azacytidine versus azacytidine alone, which can be considered a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy (thus not eligible for an allogeneic hematopoietic stem cell transplant.

Detailed description: Prospective, 1:1 randomized multicentre, open label, phase III clinical trial to evaluate efficacy and safety of pevonedistat in combination with azacytidine versus azacytidine in the treatment of naïve adult patients with acute myeloid leukemia who are not eligible for standard induction therapy due to age, co-morbidities or risk-factors.

Subjects will be randomized to one of the two treatment arms in a 1:1 ratio, both of which will have treatment cycles of 28 days:

* Arm A: Pevonedistat (PEVO) 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine (AZA) 75 mg/m2 subcutaneous (SC) administered on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycles (IV AZA can be administered for any patients who have non-tolerated local reactions)
* Arm B: AZA 75 mg/m2 SC on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle (IV AZA can be administered for any patients who have non-tolerated local reactions)

  466 subjects will be randomized in the study. Subjects will continue their study treatment until documented disease progression per Investigator assessment, unacceptable toxicity, withdrawal of consent, or the subject meets other protocol criteria for discontinuation

Eligibility criteria: Inclusion Criteria:

1. Male or female patients 18 years or older
2. Morphological diagnosis of Acute Myeloid Leukemia (AML) (WHO criteria 2008)
3. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 to 3 (ECOG 0-2 for patients greater than or equal to 75 years old).
4. Newly diagnosed AML
5. Patient must be considered be ineligible for treatment with a standard Ara-C and anthracycline induction regimen due to age or co-morbidities defined by one of the following:

   1. ≥ 75 years of age
   2. Or ≥ 18 to 74 years of age with at least one of the following:

      * ECOG Performance Status of 2 or 3;
      * Cardiac history of cardiac heart failure requiring treatment or Ejection Fraction ≤ 50% or chronic stable angina;
      * Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ≤ 65% or Forced Expiratory Volume in 1 second (FEV1) ≤ 65% or significant history of chronic pulmonary obstructive disease;
      * Glomerular filtration rate (GFR) ≥ 30 mL/min to \< 50 ml/min or levels of creatinine between the upper limit of the normal range (ULN) and 2.5 mg/dL (≤ 250 μmol/l).
      * Hepatic impairment with total bilirubin \> 1.5 to ≤ 3 × ULN or with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2.5×ULN to ≤ 5×ULN
      * Non active/controlled prior neoplastic disease
      * Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed, documented, and approved by the Sponsor before study enrollment).
6. Clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values used for randomization were obtained more than 3 days before the first dose of study drug):

   * Total bilirubin ≤ 1.5 × ULN except in patients with Gilbert's syndrome or ≤ 3 × ULN if elevation is attributed to underlying leukemia. Patients with Gilbert's syndrome may enroll with direct bilirubin ≤3 × ULN of the direct bilirubin. Elevated indirect bilirubin due to posttransfusion hemolysis is allowed.
   * ALT and AST ≤ 2.5×ULN or ≤ 5×ULN if elevation is attributed to underlying leukemia.
   * Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min (calculated by the Cockcroft Gault formula, (see Appendix 5).
   * Albumin \>2.7 g/dL.
7. Subject has a white blood cell count \<50 × 109/L. Patients who are cytoreduced with leukapheresis or with hydroxyurea may be enrolled if they meet the eligibility criteria before starting therapy.
8. Female subjects must be either postmenopausal for at least 1 year before screening (see Appendix 12 for definition) OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) must agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception (see Appendix 11), at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception). Female subjects of childbearing potential must have negative results for pregnancy test performed and must not be lactating and breastfeeding.
9. Male subjects even if surgically sterilized (i.e., status post vasectomy), who are sexually active, must agree, from Study Day 1 through at least 4 months after the last dose of study drug, to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner\] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
10. Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria:

1. Previous treatment for myelodysplastic síndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) or myeloproliferative neoplasms (MPN), with chemotherapy or other antineoplastic agents including HMAs (up to 2 cycles of Hypomethylating agents (HMA) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.
2. Subject has history MPN with BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
3. Genetic diagnosis of acute promyelocytic leukemia.
4. Eligible for intensive chemotherapy and/or allogeneic stem cell transplantation.

   * The reason a patient is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation is described in the inclusion criteria section
   * The reason a patient is not eligible for intensive chemotherapy must be documented in the electronic case report form (eCRF).
5. Patients with either clinical evidence of or history of central nervous system involvement by AML.
6. Diagnosed or treated for another malignancy within 1 year before randomization or previously diagnosed with another malignancy and have any evidence of residual disease which may compromise the administration of AZA or AZA+PEVO.
7. Psychological,social, or geographic factors that otherwise preclude the patient from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up.
8. Subject has a white blood cell count \> 50 × 109/L.
9. Contraindications for PEVO or AZA.
10. Known hypersensitivity to pevonedistat or its excipients.
11. Female patients who intend to donate eggs (ova) during the course of this study or for 4 months after receiving their last dose of study drug(s).
12. Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
13. Male patients who intend to donate sperm or father a child during the course of this study or for 4 months after receiving their last dose of study drug(s).
14. Subject is known to be positive for HIV (HIV testing is not required for eligibility assessment). Known HIV positive patients who meet the following criteria will be considered eligible:

    * Cluster of differentiation 4 (CD4) count \> 350 cells/mm3
    * Undetectable viral load
    * Maintained on modern therapeutic regimens utilizing non-cytochrome P450 (CYP)-interactive agents
    * No history of AIDS-defining opportunistic infections
15. Subject is known to be positive for hepatitis B or C infection, with the exception of those with an undetectable viral load within 3 months (Hepatitis B or C testing is not required for eligibility assessment).
16. Known hepatic cirrhosis or severe preexisting hepatic impairment.
17. Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV; see Appendix 7), and/or ST elevation myocardial infarction within 6 months before first dose, or severe symptomatic pulmonary hypertension requiring pharmacologic therapy, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. As an example, well-controlled atrial fibrillation would not be an exclusion whereas uncontrolled atrial fibrillation would be an exclusion. Patients with medical comorbidities that will preclude safety evaluation of the combination should not be enrolled.
18. Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.
19. Treatment with strong Cytochrome P450, family 3, subfamily A (CYP3A) inducers (see Appendix 8) within 14 days before the first dose of pevonedistat.
20. Patients with uncontrolled coagulopathy or bleeding disorder.
21. High blood pressure which cannot be controlled by standard treatments
22. Prolonged rate corrected QT (QTc) interval ≥ 500 msec, calculated according to institutional guidelines.
23. As infection is a common feature of AML, patients with active infection are permitted to enroll provided that the infection is under control and no signs of systemic inflammatory response beyond low grade fever that makes patient clinically unstable in the opinion of the investigator. Patients with uncontrolled infection shall not be enrolled until infection is treated and brought under control.
24. Patients who have received an investigational agent (for any indication) within 5 half-lives of the agent and until toxicity from this has resolved to grade 1 or less; if the half-life of the agent is unknown, patients must wait 4 weeks prior to first dose of study treatment.
25. Systemic antineoplastic therapy for malignant conditions other than myeloid neoplasms within 14 days before the first dose of any study drug.

Primary outcomes:
measure: Overall survival (OS)
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Event-free survival (EFS)
timeFrame: through study completion, an average of 1 year
measure: Composite complete remission
timeFrame: through study completion, an average of 1 year
measure: Overall response rate
timeFrame: through study completion, an average of 1 year
measure: Cumulative incidence of relapse
timeFrame: through study completion, an average of 1 year
measure: Health status/quality of life
timeFrame: through study completion, an average of 1 year
measure: Health status/quality of life
timeFrame: through study completion, an average of 1 year
measure: Use of medical resources determined by the use of antibiotics
timeFrame: through study completion, an average of 1 year
measure: Use of medical resources determined by the use of transfusions
timeFrame: through study completion, an average of 1 year
measure: Use of medical resources determined by the number of hospital admissions
timeFrame: through study completion, an average of 1 year
measure: Pharmacokinetic
timeFrame: At day 1, 3 and 5 of cycle 1, cycle 2 and cycle 3 (each cycle is 28 days)
measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
timeFrame: through study completion (an average of 1 year)
measure: Quality of composite complete remission determined by the minimal residual disease determined by RT-qPCR in the NPM1+ and CBF subsets and in bone marrow by MPFC in the remaining patients
timeFrame: through study completion, an average of 1 year
measure: Overall survival based on somatic mutations
timeFrame: through study completion, an average of 1 year
measure: Event free survival based on somatic mutations
timeFrame: through study completion, an average of 1 year
measure: Overall response rate based on somatic mutations
timeFrame: through study completion, an average of 1 year
measure: Overall survival based on cytogenetic abnormalities
timeFrame: through study completion, an average of 1 year
measure: Event free survival based on cytogenetic abnormalities
timeFrame: through study completion, an average of 1 year
measure: Overall response rate based on cytogenetic abnormalities
timeFrame: through study completion, an average of 1 year
measure: Red blood cells transfusion transfusion Independence (no use of red blood cells transfusion for a period of at least 8 weeks)
timeFrame: through study completion, an average of 1 year
measure: Platelet transfusion Independence (no use of platelets transfusión for a period of at least 8 weeks)
timeFrame: through study completion, an average of 1 year
measure: Biomarkers (CBF) predictive of PEVO activity
timeFrame: through study completion, an average of 1 year
measure: Biomarkers (FLT3-ITD) predictive of PEVO activity
timeFrame: through study completion, an average of 1 year
measure: Biomarkers (NPM1) predictive of PEVO activity
timeFrame: through study completion, an average of 1 year
measure: Biomarkers (P53) predictive of PEVO activity
timeFrame: through study completion, an average of 1 year
measure: Biomarkers (IDH1/IDH2 ) predictive of PEVO activity
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Santiago De Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago
state: A Coruña
city: Vitoria
country: Spain
facility: Hospital Txagorritxu
state: Alava
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias
state: Asturias
city: Badalona
country: Spain
facility: ICO Badalona- Hospital Universitari Germans Trias i Pujol
state: Barcelona
city: Hospitalet del Llobregat
country: Spain
facility: ICO Hospitalet- Hospital Duran i Reynals
state: Barcelona
city: San Sebastián
country: Spain
facility: Hospital Universitario Donostia
state: Guipuzcoa
city: Jaén
country: Spain
facility: Complejo Hospitalario de Jaén
state: Jaen
city: Las Palmas De Gran Canaria
country: Spain
facility: Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín
state: Las Palmas
city: Pozuelo De Alarcón
country: Spain
facility: Hospital Universitario Quirón Madrid
state: Madrid
city: San Sebastián De Los Reyes
country: Spain
facility: Hospital Universitario Infanta Sofía
state: Madrid
city: Málaga
country: Spain
facility: Hospital Regional Universitario de Málaga
state: Malaga
city: Málaga
country: Spain
facility: Hospital Universitario Virgen de la Victoria
state: Malaga
city: Cartagena
country: Spain
facility: Hospital General Universitario Santa Lucía
state: Murcia
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: Santa Cruz De Tenerife
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
state: Sevila
city: Talavera De La Reina
country: Spain
facility: Hospital General Nuestra Señora del Prado
state: Toledo
city: Baracaldo
country: Spain
facility: Hospital Universitario de Cruces
state: Vizcaya
city: Bilbao
country: Spain
facility: Hospital Universitario de Basurto
state: Vizcaya
city: Galdakao
country: Spain
facility: Hospital Universitario de Galdakao
state: Vizcaya
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario A Coruña
city: Albacete
country: Spain
facility: Complejo Hospitalario Universitario de Albacete
city: Alicante
country: Spain
facility: Hospital General Universitario de Alicante
city: Almería
country: Spain
facility: Complejo Hospitalario Torrecárdenas
city: Arrecife
country: Spain
facility: Hospital Dr. José Molina Orosa
city: Avilés
country: Spain
facility: Hospital San Agustin
city: Badajoz
country: Spain
facility: Hospital Universitario de Badajoz
city: Barcelona
country: Spain
facility: Hospital del Mar
city: Benalmádena
country: Spain
facility: Hospital Vithas Xanit Internacional
city: Burgos
country: Spain
facility: Hospital Universitario de Burgos
city: Cadiz
country: Spain
facility: Hospital Universitario Puerta del Mar
city: Castelló
country: Spain
facility: Hospital General Universitario de Castellón
city: Cáceres
country: Spain
facility: Complejo Hospitalario de Cáceres
city: Córdoba
country: Spain
facility: Complejo Hospitalario Regional Reina Sofía
city: Elche
country: Spain
facility: Hospital General Universitario de Elche
city: Gerona
country: Spain
facility: ICO Girona- Hospital Universitari Dr Josep Trueta
city: Guadalajara
country: Spain
facility: Hospital Universitario de Guadalajara
city: Huelva
country: Spain
facility: Hospital Universitario Juan Ramón Jiménez
city: Huesca
country: Spain
facility: Hospital San Jorge
city: Lugo
country: Spain
facility: Complejo Hospitalario Lucus Augusti
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Madrid
country: Spain
facility: Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario Fundación Jiménez Díaz
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario Madrid Norte Sanchinarro
city: Murcia
country: Spain
facility: Hospital General Universitario Morales Meseguer
city: Málaga
country: Spain
facility: Hospital Quirón de Málaga
city: Ourense
country: Spain
facility: Complexo Hospitalario Universitario de Ourense
city: Palma de Mallorca
country: Spain
facility: Hospital Son Llàtzer
city: Pontevedra
country: Spain
facility: Complexo Hospitalario de Pontevedra
city: Salamanca
country: Spain
facility: Hospital Universitario de Salamanca
city: Santa Cruz De Tenerife
country: Spain
facility: Complejo Hospitalario Universitario Nuestra Señora de la Candelaria
city: Segovia
country: Spain
facility: Hospital General de Segovia
city: Sevilla
country: Spain
facility: Hospital de Valme
city: Tarragona
country: Spain
facility: Hospital Universitari Joan XXIII
city: Toledo
country: Spain
facility: Hospital Virgen de la Salud
city: Valencia
country: Spain
facility: Hospital Clínico Universitario de Valencia
city: Valencia
country: Spain
facility: Hospital Universitario Dr. Peset Aleixandre
city: Valencia
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Valladolid
country: Spain
facility: Hospital Clínico Universitario de Valladolid
city: Zaragoza
country: Spain
facility: Hospital Clínico Universitario Lozano Blesa
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
city: Ávila
country: Spain
facility: Complejo Asistencial de Ávila
Study officials:
References:
citation: Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
citation: Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.
citation: Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884.
citation: Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010 Dec 15;70(24):10310-20. doi: 10.1158/0008-5472.CAN-10-2062.
citation: Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011 Apr 15;71(8):3042-51. doi: 10.1158/0008-5472.CAN-10-2122. Epub 2011 Apr 12.
citation: Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.
citation: Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.
citation: Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Dohner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
citation: Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.
citation: Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Invest New Drugs. 2016 Aug;34(4):439-49. doi: 10.1007/s10637-016-0348-5. Epub 2016 Apr 8.